Proposed Mechanism BPC-157 appears to work through multiple pathways: Maintaining vesicular integrity (affecting VMATs and dopamine transporters) Possibly occupying its own vesicular storage sites Competing for dopamine receptor binding Functionally substituting when dopaminergic neurons are lost This last property, essentially filling in for missing dopamine function, would explain why the peptide counteracts both receptor agonists (apomorphine) and antagonists (haloperidol, fluphenazine, clozapine, sulpiride) with equal effectiveness
Need extra help to support healthy blood pressure
Beyond digestive effects, patients report fatigue, headaches, and taste changes in smaller percentages
Current WADA Status (2026) No semaglutide and tirzepatide are not banned by WADA in 2026
Consistent Treatment: If your therapy involves multiple sessions, be consistent with your appointments
L-carnitine might elevate PPAR- expression, and then activate SOD and CAT, resulting in a decrease in extracellular H 2 O 2 levels and prevention of liver damage
